Quality of Life Effects of Ovarian Suppression in the Suppression of Ovarian Function Trial

被引：1
|
作者：
Tomao, Federica [1 ,2 ]
Papa, Anselmo
Tomao, Silverio [3 ]
机构：
[1] European Inst Oncol, Milan, Italy
[2] Univ Rome Sapienza, Rome, Italy
[3] Univ Rome Sapienza, Latina, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 34期
关键词：
PREMENOPAUSAL BREAST-CANCER; PATIENT-REPORTED OUTCOMES; ADJUVANT EXEMESTANE; ENDOCRINE TREATMENT; WOMEN; TAMOXIFEN;
D O I：
10.1200/JCO.2016.68.8218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4188 / +
页数：2
相关论文
共 50 条
  • [1] Quality of Life Effects of Ovarian Suppression in the Suppression of Ovarian Function Trial Reply
    Ribi, Karin
    Bernhard, Jurg
    Luo, Weixiu
    Regan, Meredith M.
    Fleming, Gini F.
    Francis, Prudence A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4189 - +
  • [2] A case for Tamoxifen with ovarian function suppression
    Pallavi Kopparthy
    Karen Daily
    Breast Cancer Research and Treatment, 2020, 183 : 241 - 242
  • [3] Degarelix improves suppression of ovarian function
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2019, 20 (02): : E73 - E73
  • [4] A case for Tamoxifen with ovarian function suppression
    Kopparthy, Pallavi
    Daily, Karen
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 241 - 242
  • [5] Ovarian function suppression in the adjuvant program
    Davidson, N. E.
    BREAST, 2007, 16 : S8 - S9
  • [6] Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT)
    Phillips, Kelly-Anne
    Feng, Yang
    Ribi, Karin
    Bernhard, Juerg
    Puglisi, Fabio
    Bellet, Meritxell
    Spazzapan, Simon
    Karlsson, Per
    Budman, Daniel R.
    Zaman, Khalil
    Abdi, Ehtesham A.
    Domchek, Susan M.
    Regan, Meredith M.
    Coates, Alan S.
    Gelber, Richard D.
    Maruff, Paul
    Boyle, Frances
    Forbes, John F.
    Fleming, Gini F.
    Francis, Prudence A.
    CANCER RESEARCH, 2015, 75
  • [7] Ovarian function suppression as a potential mechanism of chemotherapy
    Marti, Juan Luis Gomez
    Nasrazadani, Azadeh
    Brufsky, Adam M.
    EBIOMEDICINE, 2021, 70
  • [8] Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
    Ribi, Karin
    Luo, Weixiu
    Bernhard, Jurg
    Francis, Prudence A.
    Burstein, Harold J.
    Ciruelos, Eva
    Bellet, Meritxell
    Pavesi, Lorenzo
    Lluch, Ana
    Visini, Marilena
    Parmar, Vani
    Tondini, Carlo
    Kerbrat, Pierre
    Perello, Antonia
    Neven, Patrick
    Torres, Roberto
    Lombardi, Davide
    Puglisi, Fabio
    Karlsson, Per
    Ruhstaller, Thomas
    Colleoni, Marco
    Coates, Alan S.
    Goldhirsch, Aron
    Price, Karen N.
    Gelber, Richard D.
    Regan, Meredith M.
    Fleming, Gini F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) : 1601 - U122
  • [9] Ovarian Suppression: Early Menopause and Late Effects
    Chiara Molinelli
    Flavia Jacobs
    Guilherme Nader-Marta
    Roberto Borea
    Graziana Scavone
    Silvia Ottonello
    Piero Fregatti
    Cynthia Villarreal-Garza
    Jyoti Bajpai
    Hee Jeong Kim
    Silvia Puglisi
    Evandro de Azambuja
    Matteo Lambertini
    Current Treatment Options in Oncology, 2024, 25 : 523 - 542
  • [10] Ovarian Suppression: Early Menopause and Late Effects
    Molinelli, Chiara
    Jacobs, Flavia
    Nader-Marta, Guilherme
    Borea, Roberto
    Scavone, Graziana
    Ottonello, Silvia
    Fregatti, Piero
    Villarreal-Garza, Cynthia
    Bajpai, Jyoti
    Kim, Hee Jeong
    Puglisi, Silvia
    de Azambuja, Evandro
    Lambertini, Matteo
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (04) : 523 - 542
12345